FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2297672308> ?p ?o ?g. }

• W2297672308 endingPage "9" @default.
• W2297672308 startingPage "34" @default.
• W2297672308 abstract "Little is known about the complex stepwise process of giving up intravenous (i.v.) drugs. However, HIV risk reduction programs directed towards i.v. drug users have been accused by some opponents to encourage users to continue. In order to better assess the relationships between risk reduction and abstinence, we studied factors associated with abstinence in HIV-infected patients using i.v. drugs at enrollment in the SEROCO cohort (1988-1994).63 HIV-infected patients injecting i.v. drugs at enrollment were followed-up every 6 months with a clinical examination and a questionnaire concerning sexual and drugs practices since last consultation. Abstinence was defined as non injecting for at least 6 months. The 30 patients who became abstinent during a follow-up period of 3 years were compared to the 33 remaining.Abstinence during follow-up was not related to age at inclusion, duration of i.v. drug use, gender or marital status. However, patients who became abstinent were more likely to have a professional activity at inclusion than the remaining (70% vs 42%, p = 0.03). Before knowledge of HIV infection, frequency of injections, needle sharing and use of condoms did not differ between the 2 groups. During follow-up, behavioural changes occurred in the two groups, but were more marked in those who lately became abstinent. These latter were more likely to always inject with new needles/syringes (57% vs 18%, p = 0.003), and to use condoms with HIV-negative partners or of unknown status (73% vs 39%, p = 0.06). Professional activity and systematic use of new needles/syringes remained independently associated with abstinence in multivariate analysis.In this cohort, abstinence appeared as a stepwise process in which risk reduction preceded abstinence. This confirms that risk reduction programs do not work against those messages aimed at stopping i.v. drug use. Since this analysis selected particular subjects, enrolled in a cohort of HIV-infected patients, results should be confirmed in other samples of i.v. drugs users.Few prospective studies have described the stepwise process of giving up intravenous drug (IV) use. In an effort to deepen the understanding of the relationship between risk reduction related to IV drug use and giving up such drug use, the authors studied factors associated with IV drug abstinence among HIV-infected patients using IV drugs at their enrollment in the multicenter French cohort SEROCO between 1988 and 1994. 63 HIV-infected patients injecting IV drugs at enrollment were followed clinically every 6 months and with a questionnaire on their sexual practices and drug use since their most recent consultations. The termination of drug use was defined as not using drugs for a period of at least 6 months. The 30 subjects who gave up IV drug use over the 3-year follow-up were compared to the 33 subjects who continued using IV drugs. Those who gave up IV drugs were more likely to be professionally active at enrollment than those who kept injecting, they more often used during the follow-up period new injection materials for each injection, and more often used condoms with HIV-negative partners and those of unknown serostatus. The abandonment of IV drug use in this study followed a stepwise process in which the reduction of risks preceded the eventual cessation of drug use." @default.
• W2297672308 created "2016-06-24" @default.
• W2297672308 creator A5006119914 @default.
• W2297672308 creator A5017785517 @default.
• W2297672308 creator A5038601523 @default.
• W2297672308 creator A5048785777 @default.
• W2297672308 creator A5077270648 @default.
• W2297672308 creator A5085571849 @default.
• W2297672308 creator A5087281326 @default.
• W2297672308 date "1998-02-01" @default.
• W2297672308 modified "2023-09-25" @default.
• W2297672308 title "[Risk reduction and intravenous drug use abstinence in patients with HIV infection. The SEROCO group]." @default.
• W2297672308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9533232" @default.
• W2297672308 hasPublicationYear "1998" @default.
• W2297672308 type Work @default.
• W2297672308 sameAs 2297672308 @default.
• W2297672308 citedByCount "0" @default.
• W2297672308 crossrefType "journal-article" @default.
• W2297672308 hasAuthorship W2297672308A5006119914 @default.
• W2297672308 hasAuthorship W2297672308A5017785517 @default.
• W2297672308 hasAuthorship W2297672308A5038601523 @default.
• W2297672308 hasAuthorship W2297672308A5048785777 @default.
• W2297672308 hasAuthorship W2297672308A5077270648 @default.
• W2297672308 hasAuthorship W2297672308A5085571849 @default.
• W2297672308 hasAuthorship W2297672308A5087281326 @default.
• W2297672308 hasConcept C118552586 @default.
• W2297672308 hasConcept C126322002 @default.
• W2297672308 hasConcept C2776983459 @default.
• W2297672308 hasConcept C2778782608 @default.
• W2297672308 hasConcept C2779076696 @default.
• W2297672308 hasConcept C2779379456 @default.
• W2297672308 hasConcept C2780035454 @default.
• W2297672308 hasConcept C2780586045 @default.
• W2297672308 hasConcept C2780687700 @default.
• W2297672308 hasConcept C2780727368 @default.
• W2297672308 hasConcept C2781354955 @default.
• W2297672308 hasConcept C2908647359 @default.
• W2297672308 hasConcept C2986817661 @default.
• W2297672308 hasConcept C3013748606 @default.
• W2297672308 hasConcept C3019645122 @default.
• W2297672308 hasConcept C512399662 @default.
• W2297672308 hasConcept C71924100 @default.
• W2297672308 hasConcept C72563966 @default.
• W2297672308 hasConcept C99454951 @default.
• W2297672308 hasConceptScore W2297672308C118552586 @default.
• W2297672308 hasConceptScore W2297672308C126322002 @default.
• W2297672308 hasConceptScore W2297672308C2776983459 @default.
• W2297672308 hasConceptScore W2297672308C2778782608 @default.
• W2297672308 hasConceptScore W2297672308C2779076696 @default.
• W2297672308 hasConceptScore W2297672308C2779379456 @default.
• W2297672308 hasConceptScore W2297672308C2780035454 @default.
• W2297672308 hasConceptScore W2297672308C2780586045 @default.
• W2297672308 hasConceptScore W2297672308C2780687700 @default.
• W2297672308 hasConceptScore W2297672308C2780727368 @default.
• W2297672308 hasConceptScore W2297672308C2781354955 @default.
• W2297672308 hasConceptScore W2297672308C2908647359 @default.
• W2297672308 hasConceptScore W2297672308C2986817661 @default.
• W2297672308 hasConceptScore W2297672308C3013748606 @default.
• W2297672308 hasConceptScore W2297672308C3019645122 @default.
• W2297672308 hasConceptScore W2297672308C512399662 @default.
• W2297672308 hasConceptScore W2297672308C71924100 @default.
• W2297672308 hasConceptScore W2297672308C72563966 @default.
• W2297672308 hasConceptScore W2297672308C99454951 @default.
• W2297672308 hasIssue "1" @default.
• W2297672308 hasLocation W22976723081 @default.
• W2297672308 hasOpenAccess W2297672308 @default.
• W2297672308 hasPrimaryLocation W22976723081 @default.
• W2297672308 hasRelatedWork W1651380465 @default.
• W2297672308 hasRelatedWork W1916116292 @default.
• W2297672308 hasRelatedWork W2336039220 @default.
• W2297672308 hasRelatedWork W2348663518 @default.
• W2297672308 hasRelatedWork W2379311004 @default.
• W2297672308 hasRelatedWork W2417984407 @default.
• W2297672308 hasRelatedWork W3000731756 @default.
• W2297672308 hasRelatedWork W4248330537 @default.
• W2297672308 hasRelatedWork W940819186 @default.
• W2297672308 hasRelatedWork W2198566944 @default.
• W2297672308 hasVolume "46" @default.
• W2297672308 isParatext "false" @default.
• W2297672308 isRetracted "false" @default.
• W2297672308 magId "2297672308" @default.
• W2297672308 workType "article" @default.